<DOC>
	<DOCNO>NCT02146742</DOCNO>
	<brief_summary>Three group 8 Japanese male give single ascend dos ASP1707 placebo ass safety tolerability , evaluate absorb , metabolize distribute body .</brief_summary>
	<brief_title>A Study Assess Effects Single Ascending Doses ASP1707 Healthy Young Japanese Male Subjects</brief_title>
	<detailed_description>The first group receive low dose last group receive high dose . ASP1707 match placebo administer single dose fast condition . Screening take place Day -22 Day -2 . Subjects admit clinic Day -1 remain Day 5 . An end study visit ( ESV ) take place 7-14 day discharge . Escalation next high dose take place review safety tolerability data previous dose . Safety assessment perform throughout study . Plasma urine sample collect pharmacokinetics ( PK ) analysis . Serum sample collect pharmacodynamic ( PD ) analysis .</detailed_description>
	<criteria>Born Japan Both parent Japanese descent Time reside outside Japan exceed 5 year Maintains Japanese life style include diet Male subject must nonfertile , i.e . surgically sterilize must practice effective contraceptive method Subjects outofrange T level serum screen Subjects history cancer</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>ASP1707</keyword>
	<keyword>Japanese subject</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>